Arrowhead Pharmaceuticals (ARWR) Fundamental Analysis: Revenue, Earnings & Valuation

6.03 / 10

Outperform

Fundamental analysis rates ARWR as Outperform with a 6.0/10 rating. Strengths include high inventory turnover (106.6) and a 100% gross margin, while current and fixed asset turnover lag. Asset‑MV, Profit‑MV and Cash‑MV factors score strongly, indicating solid valuation.

Analysis Checks(7/10)

Revenue-MV

Value-1.29

Score1/3

Weight8.46%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight10.27%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight2.18%

1M Return1.67%

Profit-MV

Value-1.89

Score3/3

Weight18.94%

1M Return9.40%

Income tax / Total profit (%)

Value41.56

Score2/3

Weight1.21%

1M Return0.98%

Current assets turnover ratio

Value1.01

Score0/3

Weight-1.80%

1M Return-1.61%

Fixed assets turnover ratio

Value2.16

Score1/3

Weight-1.26%

1M Return-1.13%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight5.10%

1M Return4.08%

Asset-MV

Value-0.55

Score2/3

Weight23.60%

1M Return13.10%

Cash-MV

Value-2.35

Score3/3

Weight33.29%

1M Return15.07%

Is ARWR undervalued or overvalued?

ARWR scores 6.03/10 on fundamentals and holds a Discounted valuation at present. Backed by its 5.78% ROE, 21.41% net margin, 42.07 P/E ratio, 15.12 P/B ratio, and 131.07% earnings growth, these metrics solidify its Outperform investment rating.